SpinalCyte was issued Australian Patent No. 2015202319, “Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor.”
The patent addresses the production of chondrocytes or chondrocyte-like cells using fibroblasts in vivo with mechanical stress and low oxygen tension.
SpinalCyte’s patent portfolio includes 24 U.S. and foreign patents issued and 45 patents pending. The company, which is funded entirely by angel investors, is developing the use of CybroCell human dermal fibroblasts for spinal nucleus replacement.
SpinalCyte was issued Australian Patent No. 2015202319, “Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor.”
The patent addresses the production of chondrocytes or chondrocyte-like cells using fibroblasts in vivo with mechanical stress and low oxygen tension.
SpinalCyte’s patent portfolio includes 24 U.S....
SpinalCyte was issued Australian Patent No. 2015202319, “Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor.”
The patent addresses the production of chondrocytes or chondrocyte-like cells using fibroblasts in vivo with mechanical stress and low oxygen tension.
SpinalCyte’s patent portfolio includes 24 U.S. and foreign patents issued and 45 patents pending. The company, which is funded entirely by angel investors, is developing the use of CybroCell human dermal fibroblasts for spinal nucleus replacement.
Copy to clipboard 
